Prevalence, pathophysiology and management of itch in epidermolysis bullosa.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
accepted:
14
08
2020
pubmed:
19
8
2020
medline:
4
6
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Epidermolysis bullosa (EB) is a highly diverse group of inherited skin disorders, resulting from mutations in genes encoding proteins of the dermoepidermal junction. Itch (pruritus) is one of the most common symptoms across all EB subtypes. It occurs in blistered or wounded sites, or manifests as a generalized phenomenon, thereby affecting both intact skin and healing wounds. The mechanism of pruritus in EB is unclear. It is likely that skin inflammation secondary to barrier disruption, wound healing cascades and dysregulated activation of epidermal sensory nerve endings are all involved in its pathophysiology on the molecular and cellular level. Understanding these mechanisms in depth is crucial in developing optimized treatments for people with EB and improving quality of life. This review summarizes current evidence on the prevalence, mechanisms and management of itch in EB.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
816-825Subventions
Organisme : DebRA UK
ID : RE12474
Informations de copyright
© 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Has C, Bauer JW, Bodemer Cet al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol 2020; 183:614-27.
Bruckner AL. Supportive care: bathing, wound care, nutrition, pain and itch management, psychosocial support, palliation. In: Blistering Diseases (Murrell DF, ed), Berlin: Springer, 2015; 653-66.
Pope E, Lara-Corrales I, Mellerio Jet al. A consensus approach to wound care in epidermolysis bullosa. J Am Acad Dermatol 2012; 67:904-17.
Snauwaert JJ, Yuen WY, Jonkman MFet al. Burden of itch in epidermolysis bullosa. Br J Dermatol 2014; 171:73-8.
Mauritz P, Jonkman MF, Visser SSet al. Impact of painful wound care in epidermolysis bullosa during childhood: an interview study with adult patients and parents. Acta Derm Venereol 2019; 99:783-8.
Goldschneider KR, Lucky AW. Pain management in epidermolysis bullosa. Dermatol Clin 2010; 28:273-82, ix.
Jeon IK, On HR, Kim SC. Quality of life and economic burden in recessive dystrophic epidermolysis bullosa. Ann Dermatol 2016; 28:6-14.
Dalgard FJ, Svensson A, Halvorsen JAet al. Itch and mental health in dermatological patients across Europe: a cross-sectional study in 13 countries. J Invest Dermatol 2020; 140:568-73.
Ayasse MT, Buddenkotte J, Alam Met al. Role of neuroimmune circuits and pruritus in psoriasis. Exp Dermatol 2020; 29:414-26.
Nakashima C, Ishida Y, Kitoh Aet al. Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. Exp Dermatol 2019; 28:1405-11.
Talagas M, Lebonvallet N, Berthod F, Misery L. Cutaneous nociception: role of keratinocytes. Exp Dermatol 2019; 28:1466-9.
Steinhoff M, Schmelz M, Szabó IL, Oaklander AL. Clinical presentation, management, and pathophysiology of neuropathic itch. Lancet Neurol 2018; 17:709-20.
Steinhoff M, Buddenkotte J, Lerner EA. Role of mast cells and basophils in pruritus. Immunol Rev 2018; 282:248-64.
Werfel T, Allam JP, Biedermann Tet al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138:336-49.
Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol 2018; 142:1375-90.
Storan ER, O'Gorman SM, McDonald ID, Steinhoff M. Role of cytokines and chemokines in itch. Handb Exp Pharmacol 2015; 226:163-76.
Moormann C, Artuc M, Pohl Eet al. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol 2006; 126:746-55.
Steinhoff M, Bienenstock J, Schmelz Met al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006; 126:1705-18.
Cevikbas F, Steinhoff M, Ikoma A. Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development. CNS Neurosci Ther 2011; 17:742-9.
Meng J, Moriyama M, Feld Met al. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol 2018; 141:1677-89.e8.
Oetjen LK, Mack MR, Feng Jet al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 2017; 171:217-28:e13.
Wilson SR, Thé L, Batia LMet al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013; 155:285-95.
Pogatzki-Zahn EM, Pereira MP, Cremer Aet al. Peripheral sensitization and loss of descending inhibition is a hallmark of chronic pruritus. J Invest Dermatol 2020; 140:203-11.e4.
Dawn A, Papoiu AD, Chan YHet al. Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol 2009; 160:642-4.
Danial C, Adeduntan R, Gorell ESet al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol 2015; 32:53-9.
van Scheppingen C, Lettinga AT, Duipmans JCet al. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm Venereol 2008; 88:143-50.
Davila-Seijo P, Hernandez-Martin A, Morcillo-Makow Eet al. Prioritization of therapy uncertainties in dystrophic epidermolysis bullosa: where should research direct to? an example of priority setting partnership in very rare disorders. Orphanet J Rare Dis 2013; 8:61.
Vivehanantha S, Carr RA, McGrath JAet al. Epidermolysis bullosa pruriginosa: a case with prominent histopathologic inflammation. JAMA Dermatol 2013; 149:727-31.
Saraiya A, Yang CS, Kim Jet al. Dermal eosinophilic infiltrate in junctional epidermolysis bullosa. J Cutan Pathol 2015; 42:559-63.
Nomura M, Hamasaki YI, Katayama Iet al. Eosinophil infiltration in three patients with generalized atrophic benign epidermolysis bullosa from a Japanese family: molecular genetic and immunohistochemical studies. J Hum Genet 2005; 50:483-9.
Grunwald MH, Amichai B, Avinoach Iet al. Dystrophic epidermolysis bullosa associated with eosinophilic infiltrate and elevated serum IgE. Pediatr Dermatol 1999; 16:16-8.
Borrego L, Maynard B, Peterson EAet al. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am J Pathol 1996; 148:897-909.
Engineer L, Bhol K, Kumari S, Razzaque Ahmed A. Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation. Cytokine 2001; 13:32-8.
Hashimoto T, Kursewicz CD, Fayne RAet al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol 2020; 83:53-62.
Campion M, Smith L, Gatault Set al. Interleukin-4 and interleukin-13 evoke scratching behaviour in mice. Exp Dermatol 2019; 28:1501-4.
Zhang Y, Hwang BJ, Liu Zet al. BP180 dysfunction triggers spontaneous skin inflammation in mice. Proc Natl Acad Sci USA 2018; 115:6434-9.
Yoneda K, Furukawa T, Zheng YJet al. An autocrine/paracrine loop linking keratin 14 aggregates to tumor necrosis factor alpha-mediated cytotoxicity in a keratinocyte model of epidermolysis bullosa simplex. J Biol Chem 2004; 279:7296-303.
Miao X, Huang Y, Liu TTet al. TNF-α/TNFR1 Signaling is required for the full expression of acute and chronic itch in mice via peripheral and central mechanisms. Neurosci Bull 2018; 34:42-53.
Steinhoff M, Stander S, Seeliger Set al. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003; 139:1479-88.
Lu H, Chen J, Planko Let al. Induction of inflammatory cytokines by a keratin mutation and their repression by a small molecule in a mouse model for EBS. J Invest Dermatol 2007; 127:2781-9.
Wally V, Lettner T, Peking Pet al. The pathogenetic role of IL-1β in severe epidermolysis bullosa simplex. J Invest Dermatol 2013; 133:1901-3.
Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 2008; 226:132-46.
Castela E, Tulic MK, Rozières Aet al. Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment. Br J Dermatol 2019; 180:357-64.
Fletcher JM, Moran B, Petrasca A, Smith CM. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol 2020; 201:121-34.
Strober BE, Germino R, Guana Aet al. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. J Dermatolog Treat 2020; 31:333-41.
Paller AS, Seyger MMB, Magarinos GAet al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol 2020; 183:231-41.
Esposito S, Guez S, Orenti Aet al. Autoimmunity and cytokine imbalance in inherited epidermolysis bullosa. Int J Mol Sci 2016; 17:1625.
Heinemann A, He Y, Zimina Eet al. Induction of phenotype modifying cytokines by FERMT1 mutations. Hum Mutat 2011; 32:397-406.
Hashimoto T, Kursewicz CD, Fayne RAet al. Mechanisms of itch in stasis dermatitis: significant role of Il-31 from macrophages. J Invest Dermatol 2020; 140:850-9.e3.
Breitenbach JS, Rinnerthaler M, Trost Aet al. Transcriptome and ultrastructural changes in dystrophic Epidermolysis bullosa resemble skin aging. Aging (Albany NY) 2015; 7:389-411.
Masuoka M, Shiraishi H, Ohta Set al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 2012; 122:2590-600.
Yamaguchi Y. Periostin in skin tissue and skin-related diseases. Allergol Int 2014; 63:161-70.
Chacón-Solano E, León C, Díaz Fet al. Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses. Br J Dermatol 2019; 181:512-22.
Mishra SK, Wheeler JJ, Pitake Set al. Periostin activation of integrin receptors on sensory neurons induces allergic itch. Cell Rep 2020; 31:107472.
Efron PA, Moldawer LL. Cytokines and wound healing: the role of cytokine and anticytokine therapy in the repair response. J Burn Care Rehabil 2004; 25:149-60.
Chen C, Schultz GS, Bloch Met al. Molecular and mechanistic validation of delayed healing rat wounds as a model for human chronic wounds. Wound Repair Regen 1999; 7:486-94.
Henderson J, Ferguson MW, Terenghi G. The feeling of healing. Plast Reconstr Surg 2012; 129:223e-e224.
Steinhoff MS, von Mentzer B, Geppetti Pet al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev 2014; 94:265-301.
Goutos I, Dziewulski P, Richardson PM. Pruritus in burns: review article. J Burn Care Res 2009; 30:221-8.
Nedelec B, LaSalle L. Postburn itch: a review of the literature. Wounds 2018; 30:E118-E124.
Mack MR, Wendelschafer-Crabb G, McAdams BDet al. Peripheral neuro-immune pathology in recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2015; 135:1193-7.
von Bischhoffshausen S, Ivulic D, Alvarez Pet al. Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy. Brain 2017; 140:1238-51.
Saffari TM, Bijlard E, Van Bodegraven EAMet al. Sensory perception and nerve fibre innervation in patients with keloid scars: an investigative study. Eur J Dermatol 2018; 28:828-9.
Schuhknecht B, Marziniak M, Wissel Aet al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol 2011; 165:85-91.
Tan Y, Ng WJ, Lee SZXet al. 3-Dimensional optical clearing and imaging of pruritic atopic dermatitis and psoriasis skin reveals downregulation of epidermal innervation. J Invest Dermatol 2019; 139:1201-4.
Hashimoto T, Yosipovitch G. Itchy body: topographical difference of itch and scratching and C nerve fibres. Exp Dermatol 2019; 28:1385-9.
Yosipovitch G, Misery L, Proksch Eet al. Skin barrier damage and itch: review of mechanisms, topical management and future directions. Acta Derm Venereol 2019; 99:1201-9.
Bchetnia M, Tremblay ML, Leclerc Get al. Expression signature of epidermolysis bullosa simplex. Hum Genet 2012; 131:393-406.
Herzog J, Rid R, Wagner Met al. Whole-transcriptome gene expression profiling in an epidermolysis bullosa simplex Dowling-Meara model keratinocyte cell line uncovered novel, potential therapeutic targets and affected pathways. BMC Res Notes 2015; 8:785.
Wagner M, Hintner H, Bauer JWet al. Gene expression analysis of an epidermolysis bullosa simplex Dowling-Meara cell line by subtractive hybridization: recapitulation of cellular differentiation, migration and wound healing. Exp Dermatol 2012; 21:111-7.
Cifuentes L, Kiritsi D, Chen Wet al. A case of junctional epidermolysis bullosa with prurigo-like lesions and reduction of collagen XVII and filaggrin. Br J Dermatol 2013; 169:195-8.
McGrath JA, Schofield OM, Eady RA. Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features. Br J Dermatol 1994; 130:617-25.
Lapinski P, Lapiere JC, Traczyk T, Chan LS. Sporadic dystrophic epidermolysis bullosa with concomitant atopic dermatitis. Br J Dermatol 1998; 138:315-20.
Mellerio JE, Ashton GH, Mohammedi Ret al. Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. J Invest Dermatol 1999; 112:984-7.
Schumann H, Has C, Kohlhase J, Bruckner-Tuderman L. Dystrophic epidermolysis bullosa pruriginosa is not associated with frequent FLG gene mutations. Br J Dermatol 2008; 159:464-9.
Ee HL, Liu L, Goh CL, McGrath JA. Clinical and molecular dilemmas in the diagnosis of familial epidermolysis bullosa pruriginosa. J Am Acad Dermatol 2007; 56 (5 Suppl.):S77-81.
Li AW, Prindaville B, Bateman STet al. Inpatient management of children with recessive dystrophic epidermolysis bullosa: a review. Pediatr Dermatol 2017; 34:647-55.
Goldschneider KR, Good J, Harrop Eet al. Pain care for patients with epidermolysis bullosa: best care practice guidelines. BMC Med 2014; 12:178.
Watkins J. Diagnosis, treatment and management of epidermolysis bullosa. Br J Nurs 2016; 25:428-31.
Danial C, Adeduntan R, Gorell ESet al. Evaluation of treatments for pruritus in epidermolysis bullosa. Pediatr Dermatol 2015; 32:628-34.
El Hachem M, Zambruno G, Bourdon-Lanoy Eet al. Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa. Orphanet J Rare Dis 2014; 9:76.
Yamasaki H, Tada J, Yoshioka T, Arata J. Epidermolysis bullosa pruriginosa (McGrath) successfully controlled by oral cyclosporin. Br J Dermatol 1997; 137:308-10.
Calikoglu E, Anadolu R. Management of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin. Acta Derm Venereol 2002; 82:380-2.
Tey HL, Lee AD, Almaani Net al. Epidermolysis bullosa pruriginosa masquerading as psychogenic pruritus. Arch Dermatol 2011; 147:956-60.
Banky JP, Sheridan AT, Storer EL, Marshman G. Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. Arch Dermatol 2004; 140:794-6.
Ozanic Bulic S, Fassihi H, Mellerio JEet al. Thalidomide in the management of epidermolysis bullosa pruriginosa. Br J Dermatol 2005; 152:1332-4.
Ranugha PS, Mohanan S, Chandrashekar Let al. Epidermolysis bullosa pruriginosa showing good response to low-dose thalidomide - a report of two cases. Dermatol Ther 2014; 27:60-3.
Rani S, Gupta A, Bhardwaj M. Epidermolysis bullosa pruriginosa: a rare entity which responded well to thalidomide. Dermatol Ther 2019; 32:e13035.
Schräder NHB, Duipmans JC, Molenbuur Bet al. Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases. Br J Dermatol 2019; 180:922-4.
McGrath JA, Burrows NP, Russell Jones R, Eady RA. Epidermolysis bullosa simplex Dowling-Meara: troublesome blistering and pruritus in an adult patient. Dermatology 1993; 186:68-71.
Shehadeh W, Sarig O, Bar Jet al. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol 2020; 182:1495-7.
Maritsi D, Martinez AE, Mellerio JEet al. An unusual case of epidermolysis bullosa complicated by persistent oligoarticular juvenile idiopathic arthritis; lessons to be learned. Pediatr Rheumatol 2011; 9:13.
Gubinelli E, Angelo C, Pacifico V. A case of dystrophic epidermolysis bullosa improved with etanercept for concomitant psoriatic arthritis. Am J Clin Dermatol 2010; 11 (Suppl. 1):53-4.
Chiou AS, Choi S, Barriga Met al. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: a randomized clinical trial. J Am Acad Dermatol 2020; 82:1415-21.
Yosipovitch G, Ständer S, Kerby MBet al. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol 2018; 78:882-91.e10.
Guttmann-Gruber C, Hofbauer JP, Tockner Bet al. The impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa. Presented at EB 2020. London, UK, 19-23 January 2020; P34.
Guttmann-Gruber C, Tockner B, Scharler Cet al. Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes. Sci Rep 2018; 8:13430.
Eichstadt S, Barriga M, Ponakala Aet al. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI Insight 2019; 4:e130554.
Rashidghamat E, Kadiyirire T, Ayis Set al. Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 2020; 83:447-54.
Gorell ES, Leung TH, Khuu P, Lane AT. Purified type I collagen wound matrix improves chronic wound healing in patients with recessive dystrophic epidermolysis bullosa. Pediatr Dermatol 2015; 32:220-5.
Nattkemper LA, Tey HL, Valdes-Rodriguez Ret al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol 2018; 138:1311-7.
Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol 2017; 18:83.
Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol 2010; 162:587-93.
Haest C, Casaer MP, Daems Aet al. Measurement of itching: validation of the Leuven Itch Scale. Burns 2011; 37:939-50.
Kimball AB, Luger T, Gottlieb Aet al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol 2016; 75:1156-61.
Simpson EL, Bieber T, Guttman-Yassky Eet al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335-48.
Stander S, Yosipovitch G, Legat FJet al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med 2020; 382:706-16.
Fowler E, Yosipovitch G. A new generation of treatments for itch. Acta Derm Venereol 2020; 100:adv00027.